The Oil-Bearing Strata of Permian Deposits of the Ashal’cha Oil Field Depending on the Content, Composition, and Thermal Effects of Organic Matter Oxidation in the Rocks

The features of the oil-bearing capacity of the productive strata of Permian deposits in the interval of 117.5-188.6 m along the section of individual wells of the Ashal’cha field of heavy superviscous oil (Tatarstan) were revealed depending on the content, composition, and thermal effects of organic matter (OM) oxidation in the rocks. It is shown that the rocks are very heterogeneous in their mineral composition and in the content of both free hydrocarbons by extraction with organic solvents and insoluble OM closely associated with the rock. The total content of OM in rocks varies from 1.72 to 9.12%. The features of group and hydrocarbon composition of extracts from rocks are revealed depending on their mineral composition and the content of organic matter in them. According to the molecular mass distribution of alkanes of normal and isoprenoid structure, extracts from rocks are differentiated according to three chemical types of oil: type A1, in which n-alkanes of composition C14 and above are present, and types A2 and B2, in which n-alkanes are destroyed to varying degrees by processes microbial destruction, which indicates a different intensity of biochemical processes in productive strata of Permian sediments. These processes lead to a decrease in the amount of OM in the rocks and an increase in the content of resins and asphaltenes in the oil extracted from them, as well as an increase in the viscosity of the oil. Using the method of differential scanning calorimetry of high pressure, it was found that the studied rock samples differ from each other in quantitative characteristics of exothermic effects in both low-temperature (LTO) 200-350°С and high-temperature (HTO) 350-600°С zones of OM oxidation. The total thermal effect of destruction processes of OM depends on the content of OM in the rocks and its composition. The research results show that when heavy oil is extracted using thermal technologies, the Permian productive strata with both low and high OM contents will be involved in the development, and the general thermal effect of the oxidation of which will contribute to increased oil recovery

DEVELOPMENT OF DYSBIOSIS AND INFLAMMATION IN RATS TREATED WITH ANTI-HELICOBACTER PYROLI THERAPY AND PREVENTION USING ANTIDYSBIOTIC DRUG "QUERTULIDON"

Shuhtina I. N., Petrenko A. A., Uspensky O. E., Gozhenko A. I., Shuhtin V. V., Bobrik L. M., Boris R. N. Развитие дисбиоза и воспаления в организме крыс, получавших антихеликобактерную терапию и их профилактика антидисбиотическим препаратом «квертулидон» = Development of dysbiosis and inflammation in rats treated with anti-helicobacter pyroli therapy and prevention using antidysbiotic drug "quertulidon". Journal of Education, Health and Sport. 2015;5(11):227-237. ISSN 2391-8306. DOIhttp://dx.doi.org/10.5281/zenodo.33876 http://ojs.ukw.edu.pl/index.php/johs/article/view/2015%3B5%2811%29%3A227-237 https://pbn.nauka.gov.pl/works/669474 Formerly Journal of Health Sciences. ISSN 1429-9623 / 2300-665X. Archives 2011–2014http://journal.rsw.edu.pl/index.php/JHS/issue/archive   Deklaracja. Specyfika i zawartość merytoryczna czasopisma nie ulega zmianie. Zgodnie z informacją MNiSW z dnia 2 czerwca 2014 r., że w roku 2014 nie będzie przeprowadzana ocena czasopism naukowych; czasopismo o zmienionym tytule otrzymuje tyle samo punktów co na wykazie czasopism naukowych z dnia 31 grudnia 2014 r. The journal has had 5 points in Ministry of Science and Higher Education of Poland parametric evaluation. Part B item 1089. (31.12.2014). © The Author (s) 2015; This article is published with open access at Licensee Open Journal Systems of Kazimierz Wielki University in Bydgoszcz, Poland and Radom University in Radom, Poland Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. This is an open access article licensed under the terms of the Creative Commons Attribution Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non commercial use, distribution and reproduction in any medium, provided the work is properly cited. This is an open access article licensed under the terms of the Creative Commons Attribution Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non commercial use, distribution and reproduction in any medium, provided the work is properly cited. The authors declare that there is no conflict of interests regarding the publication of this paper. Received: 25.09.2015. Revised 25.10.2015. Accepted: 10.11.2015.   УДК 616.33:342.092   РАЗВИТИЕ ДИСБИОЗА И ВОСПАЛЕНИЯ В ОРГАНИЗМЕ КРЫС, ПОЛУЧАВШИХ АНТИХЕЛИКОБАКТЕРНУЮ ТЕРАПИЮ И ИХ ПРОФИЛАКТИКА АНТИДИСБИОТИЧЕСКИМ ПРЕПАРАТОМ «КВЕРТУЛИДОН» DEVELOPMENT OF DYSBIOSIS AND INFLAMMATION IN RATS TREATED WITH ANTI-HELICOBACTER PYROLI THERAPY AND PREVENTION USING ANTIDYSBIOTIC DRUG "QUERTULIDON"   И. Н. Шухтина1, А. А. Петренко2, О. Е. Успенский3, А. И. Гоженко1, В. В. Шухтин1, Л. М. Бобрик4, Р. Н. Борис1 I. N. Shuhtina1, A. A. Petrenko2, O. E. Uspensky3, A. I. Gozhenko1, V. V. Shuhtin1, L. M. Bobrik4, R. N. Boris1   1ГУ «Украинский НИИ медицины транспорта МЗУ» (г. Одесса) 2 ГУ «Институт стоматологии НАМН» (г. Одесса) 3 Харьковский национальный медицинский университет 4Одесский национальный медицинский университет 1Ukrainian Research Institute for Medicine of Transport 2SE«The Institute of Stomatology of the National acfdemie of medical science of Ukraine» 3Kharkiv National Medical University 4Odessa National Medical University   Summary   Aim: To determine the preventive effect of the new antidysbiotic drug "Quertulidon" exercising the anti-helicobacter pyroli therapy (AHBT). Materials and methods: Rats have received AHBT (omeprazole in a dose of 1.3 mg / kg, amoxil in a dose of 50 mg / kg and clarithromycin in a dose of 7.5 mg / kg) per os for 8 days. The core group have been receiving oral administrations of phytogel "Quertulidon" (containing imudon, inulin, quercetin and calcium citrate) for 11 days extra. On the day 12, after euthanasia, blood, serum and tissue homogenates (liver, gums, mucous membranes of stomach and cheeks) were analyzed. In blood there were determined neutrophils, lymphocytes and lymphocytic index (LI — the ratio of lymphocytes to neutrophils). In serum and tissue homogenates there were determined inflammation markers (MDA and elastase), the rate of microbial contamination (by urease), the indicator of non-specific immunity (lysozyme) and the degree of dysbiosis by Levitsky. Results: AHBT induced the 3-fold increase in LI due to the decrease in the number of neutrophils. AHBT also induced the increase in the MDA, elastase and urease levels; it did the decrease in the lysozyme activity and large raise (2.5 — 5 times) of the degree of dysbiosis. Oral application of quertulidon normalized the level of lysozyme, reduced LI, significantly reduced the MDA, elastase and urease levels; and reduced the degree of dysbiosis by 1.4 — 1.8 times. Conclusion: Quertulidon has immunostimulant, antidysbiotic and anti-inflammatory effect that allows to suggest it for the prevention of AHBT-related complications.   Keywords: Anti-helicobacter pylori therapy, immune deficiency, dysbiosis, inflammation, quertulidon.   Резюме   Антихеликобактерная терапия (омепразол, амоксил, кларитромицин) вызывает развитие неспецифического иммунодефицита, дисбиоза и воспаления. Оральные аппликации квертулидона (имудон, инулин, кверцетин и цитрат кальция) оказывают антидисбиотическое и противовоспалительное действие.   Ключевые слова: антихеликобактерная терапия, иммунодефицит, дисбиоз, воспаление, квертулидон.   Резюме   РОЗВИТОК ДИСБІОЗУ І ЗАПАЛЕННЯ В ОРГАНІЗМІ ЩУРІВ, ЯКІ ОТРИМУВАЛИ АНТИХЕЛІКОБАКТЕРНУ ТЕРАПІЮ ТА ЇХ ПРОФІЛАКТИКА АНТИДИСБІОТИЧНИМ ПРЕПАРАТОМ «КВЕРТУЛІДОН». Антихелікобактерна терапія (омепразол, амоксил, кларітроміцин) викликає розвиток неспецифічного імунодефіциту, дисбіозу та запалення. Оральні аплікації квертулідону (імудон, інулін, кверцетин, цитрат кальцію) здійснюють антидисбіотичну та протизапальну дію.   Ключові слова: антихелікобактерна терапія, імунодефіцит, дисбіоз, запалення, квертулідон

Development of dysbiosis and inflammation in rats treated with anti-helicobacter pyroli therapy and prevention using antidysbiotic drug "Quertulidon"

Aim: To determine the preventive effect of the new antidysbiotic drug "Quertulidon" exercising the anti-helicobacter pyroli therapy (AHBT). Materials and methods: Rats have received AHBT (omeprazole in a dose of 1.3 mg / kg, amoxil in a dose of 50 mg / kg and clarithromycin in a dose of 7.5 mg / kg) per os for 8 days. The core group have been receiving oral administrations of phytogel "Quertulidon" (containing imudon, inulin, quercetin and calcium citrate) for 11 days extra. On the day 12, after euthanasia, blood, serum and tissue homogenates (liver, gums, mucous membranes of stomach and cheeks) were analyzed. In blood there were determined neutrophils, lymphocytes and lymphocytic index (LI — the ratio of lymphocytes to neutrophils). In serum and tissue homogenates there were determined inflammation markers (MDA and elastase), the rate of microbial contamination (by urease), the indicator of non-specific immunity (lysozyme) and the degree of dysbiosis by Levitsky. Results: AHBT induced the 3-fold increase in LI due to the decrease in the number of neutrophils. AHBT also induced the increase in the MDA, elastase and urease levels; it did the decrease in the lysozyme activity and large raise (2.5 — 5 times) of the degree of dysbiosis. Oral application of quertulidon normalized the level of lysozyme, reduced LI, significantly reduced the MDA, elastase and urease levels; and reduced the degree of dysbiosis by 1.4 — 1.8 times. Conclusion: Quertulidon has immunostimulant, antidysbiotic and anti-inflammatory effect that allows to suggest it for the prevention of AHBT-related complications.Антихеликобактерная терапия (омепразол, амоксил, кларитромицин) вызывает развитие неспецифического иммунодефицита, дисбиоза и воспаления. Оральные аппликации квертулидона (имудон, инулин, кверцетин и цитрат кальция) оказывают антидисбиотическое и противовоспалительное действие.Антихелікобактерна терапія (омепразол, амоксил, кларітроміцин) викликає розвиток неспецифічного імунодефіциту, дисбіозу та запалення. Оральні аплікації квертулідону (імудон, інулін, кверцетин, цитрат кальцію) здійснюють антидисбіотичну та протизапальну дію